Evidence map›Paper›PMID 32793904›Full record

ArticlebioRxiv : the preprint server for biology2020

The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.

Jeremy Luban, Rachel Sattler, Elke Mühlberger, Jason D Graci, Liangxian Cao, Marla Weetall, Christopher Trotta, Joseph M Colacino, Sina Bavari, Caterina Strambio-De-Castillia and 13 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Jeremy Luban
Rachel Sattler
Elke Mühlberger
Jason D Graci
Liangxian Cao
Marla Weetall
Christopher Trotta
Joseph M Colacino
Sina Bavari
Caterina Strambio-De-Castillia
Ellen L Suder
Yetao Wang
Veronica Soloveva
Katherine Cintron-Lue
Nikolai A Naryshkin
Mark Pykett
Ellen M Welch
Kylie O'Keefe
Ronald Kong
Elizabeth Goodwin
Allan Jacobson
Slobodan Paessler
Stuart Peltz
PTC Therapeutics (United States) · USUniversity of Massachusetts Chan Medical School · USBoston University · USThe University of Texas Medical Branch at Galveston · USUnited States Army Medical Research Institute of Infectious Diseases · USBroad Institute · US

Funding

The HUSH complex in HIV-1 latencyR37AI147868 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JEREMY LUBAN · 2019 to 2026
$6.4M
Insight into the Ebola virus glycoprotein fusion mechanism gleaned from the 2013-2016 epidemic GP-A82V variantR01AI148784 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LUBAN, JEREMY · 2020 to 2024
$4.1M
Genetic nonsense and its consequencesR35GM122468 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JACOBSON, ALLAN S · 2017 to 2021
$2.7M
NIAID NIH HHS R01 AI148784NIAID NIH HHS R37 AI147868NIGMS NIH HHS R35 GM122468
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has created an urgent need for therapeutics that inhibit the SARS-CoV-2 virus and suppress the fulminant inflammation characteristic of advanced illness. Here, we describe the anti-COVID-19 potential of PTC299, an orally available compound that is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme of the de novo pyrimidine biosynthesis pathway. In tissue culture, PTC299 manifests robust, dose-dependent, and DHODH-dependent inhibition of SARS CoV-2 replication (EC

Identifiers

PMID32793904
PMCPMC7418718
OpenAlexW3047198938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.